Polypharmacy and Major Adverse Events in Atrial Fibrillation
Christos Tsagkaris(Aristotle University of Thessaloniki), George Giannakoulas(AHEPA University Hospital), Αναστάσιος Κάρτας(Aristotle University of Thessaloniki), Dimitrios V. Moysidis(Aristotle University of Thessaloniki), Eleftherios Panteris(Aristotle University of Thessaloniki), Αndreas S. Papazoglou(Aristotle University of Thessaloniki), Apostolos Tzikas(AHEPA University Hospital), Αlexandra Bekiaridou(Aristotle University of Thessaloniki), Ioannis Vouloagkas(Aristotle University of Thessaloniki), Athanasios Samaras(Aristotle University of Thessaloniki), Efstratios Karagiannidis(AHEPA University Hospital), Amalia Baroutidou(Aristotle University of Thessaloniki), Antreas Chatzisolomou(Aristotle University of Thessaloniki), Vasiliki Patsiou(AHEPA University Hospital), Haralambos Karvounis(Aristotle University of Thessaloniki)
Cited by 9
Related Papers
2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension
|European Heart Journal|2022|3.6k
European Society of Cardiology: cardiovascular disease statistics 2021
|European Heart Journal|2021|1.1k
EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion – an update
|EP Europace|2019|323
COVID-19 in Adults With Congenital Heart Disease
|Journal of the American College of Cardiology|2021|76
Dengue and COVID‐19: A double burden to Brazil
|Journal of Medical Virology|2021|67